PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy.  PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In addition to their use in cancer therapy, PARP inhibitors are considered a potential treatment for acute life-threatening diseases, such as stroke and myocardial infarction, as well as for long-term neurodegenerative diseases.
Mechanism of action
DNA is damaged thousands of times during each cell cycle, and that damage must be repaired.
BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for either protein is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells.
PARP1 is a protein that is important for repairing single-strand breaks ('nicks' in the DNA). If such nicks persist unrepaired until DNA is replicated (which must precede cell division), then the replication itself can cause double strand breaks to form.
Drugs that inhibit PARP1 cause multiple double strand breaks to form in this way, and in tumours with BRCA1, BRCA2 or PALB2  mutations these double strand breaks cannot be efficiently repaired, leading to the death of the cells. Normal cells that don't replicate their DNA as often as cancer cells, and that lack any mutated BRCA1 or BRCA2 still have homologous repair operating, which allows them to survive the inhibition of PARP.
Some cancer cells that lack the tumor suppressor PTEN may be sensitive to PARP inhibitors because of downregulation of Rad51, a critical homologous recombination component, although other data suggest PTEN may not regulate Rad51. Hence PARP inhibitors may be effective against many PTEN-defective tumours (e.g. some aggressive prostate cancers).
Cancer cells that are low in oxygen (e.g. in fast growing tumors) are sensitive to PARP inhibitors.
Additional mode of action for PARP inhibitors
2012: Researchers at the National Cancer Institute have discovered a significant new mechanism of action for PARP inhibitors. They have also identified differences in the toxic capabilities of three drugs in this class, which are currently being tested in clinical trials. Prior to this study, PARP inhibitors were thought to work primarily by blocking PARP enzyme activity, thus preventing the repair of DNA damage and ultimately causing cell death. In this study, scientists established that PARP inhibitors have an additional mode of action: localizing PARP proteins at sites of DNA damage, which has relevance to their anti-tumor activity. The trapped PARP protein–DNA complexes are highly toxic to cells because they block DNA replication. When the researchers tested three PARP inhibitors for their differential ability to trap PARP proteins on damaged DNA, they found that the trapping potency of the inhibitors varied widely. The PARP family of proteins in humans includes PARP1 and PARP2, which are DNA binding and repair proteins. When activated by DNA damage, these proteins recruit other proteins that do the actual work of repairing DNA. Under normal conditions, PARP1 and PARP2 are released from DNA once the repair process is underway. However, as this study shows, when they are bound to PARP inhibitors, PARP1 and PARP2 become trapped on DNA. The researchers showed that trapped PARP–DNA complexes are more toxic to cells than the unrepaired single-strand DNA breaks that accumulate in the absence of PARP activity, indicating that PARP inhibitors act as PARP poisons. These findings suggest that there may be two classes of PARP inhibitors, catalytic inhibitors that act mainly to inhibit PARP enzyme activity and do not trap PARP proteins on DNA, and dual inhibitors that both block PARP enzyme activity and act as PARP poison.
Approved for marketing
- olaparib On December 19, 2014, the US FDA approved olaparib as monotherapy (at 400 mg taken twice per day) for patients with germline BRCA mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Examples in clinical trials
With phase III results:
- Niraparib (MK-4827) Inhibitor of PARP1 and PARP2. In a phase III trial for ovarian cancer. It is reported that the primary endpoint (PFS) was met.
Started Phase III:
- Iniparib (BSI 201) for breast cancer and squamous cell lung cancer. Failed trial for triple negative breast cancer. In 2012 iniparib was determined not be a true PARP inhibitor and its mechanism of action is believed to be through other means than PARP inhibition.
- Talazoparib (BMN-673) after trials for advanced hematological malignancies and for advanced or recurrent solid tumors. it is now in phase 3 for metastatic germline BRCA mutated breast cancer.
- Veliparib (ABT-888) June 2014 in ph3 trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC).
Started Phase II:
- Olaparib (AZD-2281) for breast, ovarian and colorectal cancer. AZ
- Olaparib TOPARP-A trial for use in advanced prostate cancer (published c. April 21, 2015).
- Rucaparib (AG014699, PF-01367338) for metastatic breast and ovarian cancer.
- Veliparib (ABT-888) for metastatic melanoma.
- CEP 9722 for non–small-cell lung cancer (NSCLC)
- Eisai's E7016 (phase II in melanoma).
Started Phase I:
- 3-aminobenzamide, a prototypical PARP inhibitor
Combination with radiotherapy
The main function of radiotherapy is to produce DNA strand breaks, causing severe DNA damage and leading to cell death. Radiotherapy has the potential to kill 100% of any targeted cells, but the dose required to do so would cause unacceptable side effects to healthy tissue. Radiotherapy therefore can only be given up to a certain level of radiation exposure. Combining radiation therapy with PARP inhibitors offers promise, since the inhibitors would lead to formation of double strand breaks from the single-strand breaks generated by the radiotherapy in tumor tissue with BRCA1/BRCA2 mutations. This combination could therefore lead to either more powerful therapy with the same radiation dose or similarly powerful therapy with a lower radiation dose.
- "ZDNet Healthcare". ZDNet.
- Pam Stephan. "PARP Inhibitor and DNA Polymerase Repair - PARP Inhibitor". About.com Health.
- "Development of PARP Inhibitors: An Unfinished Story". cancernetwork.com.
- "PARP Inhibitors – More Widely Effective than First Thought". drugdiscoveryopinion.com.
- Wiggans, Alison J; Cass, Gemma KS; Bryant, Andrew; Lawrie, Theresa A; Morrison, Jo; Morrison, Jo (2015). "Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer". Reviews. doi:10.1002/14651858.CD007929.pub3.
- Graziani G, Szabó C (July 2005). "Clinical perspectives of PARP inhibitors". Pharmacol. Res. 52 (1): 109–18. doi:10.1016/j.phrs.2005.02.013. PMID 15911339.
- Buisson R; Dion-Côté A.M; et al. (2010). "Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.". Nature Structural & Molecular Biology 17 (10): 1247–54. doi:10.1038/nsmb.1915. PMID 20871615.
- McGlynn, P. and Lloyd, B. "Recombinational Repair and Restart of Damaged Replication Forks." Nature Reviews, 2002, pp.859-870
- N Engl J Med 361:123
- N Engl J Med 361:189
- Gupta A, Yang Q, Pandita RK, et al. (July 2009). "Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair". Cell Cycle 8 (14): 2198–210. doi:10.4161/cc.8.14.8947. PMID 19502790.
- "NIH study uncovers new mechanism of action for class of chemotherapy drugs". National Cancer Institute. 1 Nov 2012.
- Murai, J; et al. (2012). "Differential trapping of PARP1 and PARP2 by clinical PARP inhibitors". Cancer Research 72 (21): 5588–99. doi:10.1158/0008-5472.CAN-12-2753. PMID 23118055.
- "PARP Inhibitors in Oncology. Chemosensitizers or Single-Agent Therapeutics?" (PDF). July 2009.
- "PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans". 17 Nov 2010.
- AbbVie takes PARP inhibitor into third phase III trial. June 2014
- Tesaro’s PARP ovarian cancer drug hits PhIII goal; prepares to file. June 2016
- Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK,Penning TD, Johnson EF, Shoemaker AR. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi:10.1158/1078-0432.CCR-11-1973
- Anand G. Patel, Silvana B. De Lorenzo, Karen S. Flatten1, Guy G. Poirier, andScott H. Kaufmann. Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi:10.1158/1078-0432.CCR-11-2890
- BioMarin Pharmaceutical Inc. (28 July 2011). "BioMarin Announces Second Quarter 2011 Financial Results". prnewswire.com.
- "BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer". Benzinga.
- "Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel". clinicaltrials.gov.
- "AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer". clinicaltrials.gov.
- "Trial shows benefit of ‘BRCA-targeting’ drug in prostate cancer". icr.ac.uk.
- "Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors".
- "BeiGene Enrolls First Patient in Phase 1 Study of BGB-290". MarketWatch.
- "PARP inhibitors. ESTRO 2010. ecancer - Conference highlights and events calendar". ecancer.org.
|Wikimedia Commons has media related to PARP inhibitors.|